# Indivior Inc. clinical trials: 51 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 51 trials with Indivior Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Indivior Inc.: 51 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/indivior-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 51
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 51, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 29, 2024 | NCT06576843 | INDV-6001 Multiple-Dose Pharmacokinetic Study | Indivior Inc. | Phase 2 | Completed | Moderate to Severe Opioid Use Disorder | 123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06576843) |
| April 25, 2024 | NCT06384157 | Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder | Indivior Inc. | Phase 2 | Completed | Opioid Use Disorder | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06384157) |
| August 3, 2023 | NCT05974046 | Single Dose Study of \[14C\]-IDV184001AN (\[14C\]-IDV184001) in Healthy Adult Male Participants | Indivior Inc. | Phase 1 | Completed | Opioid Use Disorder | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05974046) |
| May 26, 2023 | NCT05878210 | Evaluating the SUBLOCADE Treatment Exit Strategy | Indivior Inc. | Observational | Completed | Opioid Use Disorder | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05878210) |
| May 16, 2023 | NCT05860959 | SUBLOCADE Long-term Outcomes | Indivior Inc. | Observational | Completed | Opioid Use Disorder | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05860959) |
| January 30, 2023 | NCT05704543 | Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations | Indivior Inc. | Phase 4 | Completed | Opioid Use Disorder | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05704543) |
| January 23, 2023 | NCT05694533 | Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults | Indivior Inc. | Phase 1 | Completed | Healthy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05694533) |
| August 6, 2021 | NCT04995029 | Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users | Indivior Inc. | Phase 4 | Completed | Moderate to Severe Opioid-use Disorder | 785 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04995029) |
| July 26, 2021 | NCT04976855 | Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder | Indivior Inc. | Phase 1 | Completed | Healthy Volunteer, Opioid-use Disorder | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04976855) |
| October 6, 2020 | NCT04577144 | An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term | Indivior Inc. | Observational | Terminated | Opioid Use Disorder | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04577144) |
| June 4, 2020 | NCT04413552 | INDV-2000 First in Human | Indivior Inc. | Phase 1 | Completed | Opioid Dependence | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04413552) |
| August 19, 2019 | NCT04060654 | SUBLOCADE Rapid Initiation Extension Study | Indivior Inc. | Phase 4 | Completed | Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04060654) |
| June 20, 2019 | NCT03993392 | SUBLOCADE Rapid Initiation Study | Indivior Inc. | Phase 4 | Completed | Opioid-use Disorder | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03993392) |
| June 7, 2019 | NCT03978832 | Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone | Indivior Inc. | Phase 4 | Completed | Schizophrenia | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03978832) |
| November 26, 2018 | NCT03752528 | Evaluation of Long-term Buprenorphine Plasma Exposure | Indivior Inc. | Observational | Completed | Opioid-use Disorder | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03752528) |
| November 20, 2018 | NCT03747341 | Buprenorphine-Fentanyl Interaction Study | Indivior Inc. | Phase 1 | Completed | Healthy, Opioid Use | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03747341) |
| October 23, 2018 | NCT03715634 | Study of a Novel Subcutaneous Depot Formulation of Buprenorphine | Indivior Inc. | Phase 1 | Completed | Opioid-use Disorder | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03715634) |
| July 30, 2018 | NCT03604861 | An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery | Indivior Inc. | Observational | Completed | Opioid-use Disorder, Opioid-related Disorders | 534 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03604861) |
| February 20, 2017 | NCT03058237 | A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers | Indivior Inc. | Phase 1 | Completed | Healthy Volunteers | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03058237) |
| December 26, 2016 | NCT03002961 | Single Ascending Dose Study of RBP-6000 | Indivior Inc. | Phase 1 | Completed | Opioid Use Disorder | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03002961) |
| September 12, 2016 | NCT02896296 | Open-Label Treatment Extension Study | Indivior Inc. | Phase 3 | Completed | Opioid Use Disorder, Opioid-related Disorders | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02896296) |
| May 11, 2016 | NCT02768649 | Single Ascending Dose Study of RBP-7000 | Indivior Inc. | Phase 1 | Completed | Schizophrenia | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02768649) |
| May 9, 2016 | NCT02765867 | Single-dose, Study of RBP-6000 in Opioid Dependent Individuals | Indivior Inc. | Phase 1 | Completed | Opioid Use Disorder | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02765867) |
| May 6, 2016 | NCT02765555 | First in Man Study of Safety, Tolerability and PK Profile of RBP-7000 | Indivior Inc. | Phase 1 | Completed | Schizophrenia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02765555) |
| February 23, 2016 | NCT02687984 | PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia | Indivior Inc. | Phase 1 | Completed | Schizophrenia | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02687984) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 13 |
| Phase 2 | 12 |
| Phase 3 | 5 |
| Phase 4 | 12 |
| Observational | 9 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 49 |
| Terminated | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Opioid-Related Disorders | 32 |
| Substance-Related Disorders | 7 |
| Schizophrenia | 7 |
| Gastroesophageal Reflux | 1 |
| Heroin Dependence | 1 |
| Behavior, Addictive | 1 |
| Hepatitis C, Chronic | 1 |
| Cocaine-Related Disorders | 1 |
| Substance Abuse, Intravenous | 1 |
| Liver Failure | 1 |
| Hepatitis C | 1 |
| Lymphoma, Follicular | 1 |
| Alcoholism | 1 |
| Alcohol-Induced Disorders | 1 |
| Alcoholic Intoxication | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Woodworking supply stores in the United States](https://specstream.ai/data/businesses/woodworking-supply-stores/united-states)
- [Coworking spaces in the United States](https://specstream.ai/data/businesses/coworking-spaces/united-states)
- [Internet marketing agencies in the United States](https://specstream.ai/data/businesses/internet-marketing-agencies/united-states)
- [Pulmonology practices in the United States](https://specstream.ai/data/businesses/pulmonology-practices/united-states)
- [Animation studios in the United States](https://specstream.ai/data/businesses/animation-studios/united-states)
- [Divorce and family law firms in the United States](https://specstream.ai/data/businesses/divorce-and-family-law-firms/united-states)
